Michael Makris/LinkedIn
Nov 12, 2025, 04:42
Michael Makris on FDA Approval of GEVV-HEM Gene Therapy for Hemophilia
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”A biotechnology company (GeneVentiv Therapeutics) has received positive FDA feedback to develop their GEVV-HEM gene therapy for hemophilia.
This is AAV based gene therapy with human factor Va as the insert.
I will want a lot of animal data showing lack of thrombogenicity before human trials.”
Read the announcement here.
Stay updated with Hemostasis Today.
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies
-
May 26, 2026, 15:22Shazmah Shaikh: One Visual Guide to Understand All Major Anticoagulants
-
May 26, 2026, 14:39Chidinma Favour։ Welcome to Day 25 of My 31-Day Stroke Awareness Series
-
May 26, 2026, 14:35Novel Insights Into Congenital and Acquired Coagulopathies – ICHCC
-
May 26, 2026, 14:24Fernanda Orsi: The Growing Impact of Hematology Research in Latin America
-
May 26, 2026, 14:23Rense Buijvoets: What If Clots Could Be Treated Exactly Where They Form?